Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.46 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.46 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31743094 | 0.86 | KDM4E (0.49) | TXNRD1TXNRD3TXNRD2CDK4CCND1 | |
| SCHEMBL9922451 | 0.86 | KDM4E (0.49) | TXNRD1TXNRD3TXNRD2CDK4CCND1 | |
| SCHEMBL31655715 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL22291406 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL22149411 | 0.77 | HTR6 (0.47) | MTNR1AMTNR1BNPC1MAPTRAB9A | |
| SCHEMBL16328854 | 0.77 | TNF (0.53) | MTNR1AMTNR1BKDM4EALDH1A1HPGD | |
| SCHEMBL349421 | 0.77 | CYP2A6 (0.42) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL31378640 | 0.77 | CYP2A6 (0.42) | CDK4CCND1CCNE2CCNE1CDK2 | |
| SCHEMBL28512873 | 0.76 | MTNR1A (0.46) | MTNR1AMTNR1BKDM4EHTR2C | |
| SCHEMBL1037299 | 0.75 | TNF (0.46) | TXNRD1TXNRD3TXNRD2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117069725-A | Imidazopyridazine substituted benzene ring derivative, preparation method, pharmaceutical composition and application | 上海赛默罗生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20220048887-A1 | IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF | NHWA PHARMA. CORPORATION (CN) | 2022-02-17 | — | — | US | disclosed |
| US-20220048887-A1 | IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF | NHWA PHARMA. CORPORATION (CN) | 2022-02-17 | — | — | US | disclosed |
| EP-3901149-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | NHWA Pharma Corporation (CN) | 2021-10-27 | — | — | EP | disclosed |
| EP-3901149-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | NHWA Pharma Corporation (CN) | 2021-10-27 | — | — | EP | disclosed |
| CN-113195486-A | Impurities of amide derivatives and application thereof | 江苏恩华药业股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2020125580-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | 江苏恩华药业股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
| WO-2020125580-A1 | IMPURITIES OF AMIDE DERIVATIVES AND USE THEREOF | 江苏恩华药业股份有限公司 | 2020-06-25 | — | — | WO | disclosed |
| CN-111320619-A | Impurities of amide-like derivatives and application | 江苏恩华药业股份有限公司 | 2020-06-23 | — | — | CN | disclosed |
| US-8524721-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067428-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234350-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | TXNRD1 878/4885TXNRD3 808/4885TXNRD2 244/4885 |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | TXNRD1 862/4885TXNRD3 1014/4885TXNRD2 333/4885 |
| US-20220048887-A1 | IMPURITIES OF AMIDE-LIKE DERIVATIVES AND USE THEREOF | NOTUM, CYP51A1, HADHB | TXNRD1 4667/4885TXNRD3 4562/4885TXNRD2 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.